Tirzepatide: The miracle keystone medicine for Metabolic Health
Hi everyone I am a 68 year old doctor from Pune, India. Being a general medicine doctor and a specialist in sexology, I have great interest in hormones, neuro-chemicals and their metabolic processing in the human body. Just wanted to share a detailed information regarding my experience with Tirzepatide. It has now been about 10 weeks since I started treatment, and I’ve lost around 5 kilos (11 pounds) so far. Also started TRT alongside. I am just about 12 kilos above my ideal weight but most of it is centred around my abdomen. I also was undergoing treatment for diabetes and hypertension. After starting Tirzepatide-TRT combo... qualitative changes in my metabolism have been quite remarkable—my energy levels feel comparable to what I experienced in my 30s and 40s, with much better day-long consistency and reduced fatigue. One of the most noticeable shifts has been in my dietary pattern. I’ve purposely gravitated toward a high-protein, high-fiber diet with significantly reduced carbohydrate intake. It didn't require much conscious effort for appetite modulation my satiety signaling got intrinsically altered. My cravings, particularly for refined carbs, have reduced substantially. Alongside this, I’ve been consistent with gym workouts, and I can clearly see improvements in muscle strength and endurance. My tennis performance, in particular, has improved to a level where I genuinely feel I’m playing with the agility and stamina of my younger years. Recovery times are also better. From a physiological standpoint, this has been a fascinating experience. My current understanding is that relative deficiency or impaired signaling of incretins like GLP-1 and GIP contributes significantly in improving health of persons with insulin resistance responsible for dysregulated appetite resulting in weight gain, with eventual progression to type 2 diabetes. The correction of this axis at the basic level appears to have profound systemic effects. What is particularly intriguing—especially from a medical perspective—is the broader neurohormonal interplay. The downstream effects of GLP-1 and GIP modulation on central appetite pathways, and possibly on other neurotransmitter systems, including endorphins and endocannabinoids, open up an entirely new dimension of metabolic regulation. The improvement in motivation, mood, and reward-driven eating behavior suggests that these agents are not merely metabolic drugs but neuro-metabolic modulators.